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Abstract 
 
Research suggests that individuals’ expectations about a drug’s effects are predictive of various 
types of substance abuse, including nonmedical prescription stimulant use (Torrealday et al., 
2008). Nonmedical prescription stimulant use, or NMPSU, refers to any use of prescription 
stimulants without a medical prescription, use of prescription stimulants for nonmedical 
purposes, or use that exceeds what is prescribed (Bavarian, Flay, Ketcham, &Smit, 2013). 
NMPSU is associated with a number of negative outcomes, including drug and alcohol abuse, 
risk-taking behavior, mental illness, physical health problems, and lower educational attainment 
(McCabe, Teter, Boyd, & Wechsler, 2005). While most previous research has focused on college 
students, there is evidence that medical students are also at high risk for NMPSU (Emanuel et al., 
2013; McNiel et al., 2011). This dissertation study investigated the usefulness of the Prescription 
Stimulant Expectancy Questionnaire–II (PSEQ–II) in identifying and classifying different types 
of prescription stimulant users in the medical student population. The results suggest that the 
PSEQ–II can effectively discriminate between users and nonusers in the medical student 
population, but not between medical and medical/nonmedical users. In addition, the results 
indicate that medical students’ expectancies about cognitive enhancement and anxiety and 
arousal correlate with past prescription stimulant use, even when ADHD symptoms are 
controlled for. These findings should help inform preventions and interventions for NMPSU in 
the medical student population. 
 Keywords: prescription stimulants, expectancies, medical students, ADHD, PSEQ–II 
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Expectancies as a Predictor of Prescription Stimulant Use Among Medical Students 
 The following dissertation study investigated the usefulness of the Prescription Stimulant 
Expectancy Questionnaire–II  (PSEQ–II) in understanding the expectancies and prescription 
stimulant use habits of medical students. Research suggests that past and future drug use can be 
predicted by individuals’ expectancies, or their expectations about a drug’s effects or 
consequences (Looby & Earleywine, 2010). The following study is a replication of an earlier 
study by Looby and Earleywine (2010), which suggested that the PSEQ–II can reliably predict 
past and future prescription stimulant use and classify individuals as medical or nonmedical 
users based on their expectancies. However, rather than sampling an educationally diverse group 
of adults, this study specifically examined full-time medical students, who may be at greater risk 
for NMPSU (Emanuel et al., 2013; McNiel et al., 2011). In addition, in order to obtain a more 
selective sample, participants were recruited through Amazon Mechanical Turk rather than 
Craigslist, as in the original experiment. The results of this study provide insight into the 
relationship between medical students’ expectancies and their prescription stimulant use habits.  
Literature Review 
Over the past few decades, prescription stimulant use has surged in the United States 
(DeSantis & Hane, 2010). Prescription stimulants are a class of drugs commonly used in the 
treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and include amphetamines (e.g., 
Adderall), dextroamphetamines (e.g., Dexedrine), and methylphenidates (e.g., Ritalin; DeSantis 
& Hane, 2010). Because of their high potential for abuse and misuse, prescription stimulants are 
currently classified as Schedule II drugs in the United States (DeSantis & Hane, 2010). They are 
only available by prescription, dispensed one month at a time, and not refillable (DeSantis & 
Hane, 2010). Despite strong attempts at regulation, the diversion of prescription stimulants to 
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individuals without valid medical prescriptions has increased dramatically in recent years 
(Pilkinton & Cannatella, 2012).  
Nonmedical prescription stimulant use. Nonmedical prescription stimulant use 
(NMPSU) is defined as any use of prescription stimulants without a medical prescription, use of 
prescription stimulants for nonmedical purposes, or use that exceeds what is prescribed 
(Bavarian et al., 2013). NMPSU is associated with a variety of negative psychological outcomes, 
including (a) depression; (b) anxiety; (c) stress, alcohol, and drug abuse; and (d) risk-taking 
behaviors (Gomes, Song, Godwin, & Toriello, 2011; Sussman, Pentz, Spriujt-Metz, & Miller, 
2006; McCabe et al., 2005). Studies of college students suggest that NMPSU is associated with 
lower grade point averages and lower academic achievement (McCabe et al., 2005). Prescription 
stimulant abuse also places individuals at risk for a variety of physical health consequences, 
including insomnia, seizures, cardiovascular problems, and even sudden death (Gomes et al., 
2011). As NMPSU has increased, so has the number of emergency room visits involving 
prescription stimulants, which more than doubled between 2005 and 2010 (Bavarian et al., 
2013).  
Recent research estimates that between 7% and 21% of the general population will 
engage in NMPSU at some point in their lifetime (Ford & Schroeder, 2009). Nonmedical 
prescription stimulant use is most prevalent among (a) Caucasians, (b) males, (c) people ages 
18–25, (d) varsity athletes, (e) persons of high socioeconomic status, (f) sorority and fraternity 
members, (g) students at colleges with competitive admission standards, and (h) students in the 
Northeast region of the United States (McCabe, Teter & Boyd, 2005; Dussault & Weyandt, 
2013). Nonmedical prescription stimulant use is also common among adults enrolled in medical 
school, dental school, pharmacy school, and other rigorous graduate programs (Pilkinton & 
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Cannatella, 2012; McNiel et al., 2011; Tuttle, Scheurich, & Ranseen, 2010).  
Research suggests that the majority of individuals who engage in NMPSU do so for 
academic reasons (Hartung et al., 2013). Students use prescription stimulants to aid focus and 
concentration, to work more efficiently, and to stay awake longer to study (Hartung et al., 2013). 
A smaller percentage of individuals use prescription stimulants to (a) control appetite, (b) lose 
weight, (c) improve athletic performance, (d) stay awake for non-academic reasons, or (e) “get 
high” (Barrett, Darredeau, Bordy, & Pihl, 2005; Judson & Langdon, 2009; Varga, 2012). 
Prescription stimulants are sometimes used as a substitute for recreational drugs that are more 
expensive or difficult to obtain, such as cocaine or ecstasy (Barrett et al., 2005). They may also 
be used in conjunction with other drugs. For example, prescription stimulants are sometimes 
used to counteract the effects of depressant drugs, such as alcohol, or to intensify the effects of 
other stimulant drugs, such as cocaine, ecstasy, or caffeine (Barrett et al., 2005). 
Prevalence of prescription stimulant use in medical school. Although several studies 
suggest that college students are at greatest risk for NMPSU, research indicates that this behavior 
is also increasing among medical students (Emanuel et al., 2013; McNiel et al., 2011). 
Approximately 8.4% of the total United States population and 4.4% of the adult population is 
diagnosed with ADHD (Pilkinton & Cannatella, 2012). Therefore, it might be expected that 
somewhere between 4.4% and 8.4% of medical students would hold a medical prescription for 
stimulant drugs. However, individuals with ADHD tend to have lower educational attainment 
than the general population, so the percentage of medical students who meet the criteria for 
ADHD would actually be expected to be lower than in other populations (Low & Feldman, 
2007). Despite these statistics, the number of medical students reporting prescription stimulant 
use is considerably higher than in the general population (Wasserman et al., 2014). In a study of 
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four Chicago-area medical schools, 18% of students reported lifetime use of prescription 
stimulants and 11% reported use of prescription stimulants during medical school (Emanuel et 
al., 2013). Similarly, when first- and second-year students were surveyed at a large school of 
osteopathic medicine, 15.2% reported using prescription stimulants to help them study during 
medical school (Wasserman et al., 2014). Yet another study found that 10% of students at an 
allopathic medical school reported lifetime prescription stimulant use (Tuttle et al., 2010).  
Recent research has also explored prescription stimulant use in graduate programs similar 
to medical school, such as pharmacy and dental schools. In a study of two pharmacy programs in 
North Carolina, 9% of students reported using prescription stimulants at least once during their 
pharmacy education (Volger, McLendon, Fuller, & Herring, 2014). At a dental school in the 
southern region of the United States, 12.4% of students reported NMPSU (McNiel et al., 2011). 
Taken as a whole, these studies all suggest that students enrolled in medical school or similar 
competitive graduate programs are at increased risk for NMPSU. 
Despite recent efforts to assess NMPSU in medical students, it is difficult to distinguish 
between medical and nonmedical prescription stimulant use in this population because of the 
strong possibility that ADHD is being over-diagnosed. One study found that 72% of medical 
students with ADHD were diagnosed after age 18, which raises questions about whether they 
actually meet the criteria (Tuttle et al., 2010). On one hand, it is possible that these students had 
mild symptoms and functioned well until academic or occupational demands exceeded their 
coping skills. On the other hand, ADHD is classified as a developmental disorder in which the 
onset of symptoms occurs before age 12. Late diagnosis suggests that an individual’s symptoms 
might be better attributed to other factors, such as environmental stressors (Tuttle et al., 2010).  
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Medical school may place individuals at risk for NMPSU for several reasons. First of all, 
medical students tend to report significant academic pressure, stress, and feelings of competition 
with their peers (Wasserman et al., 2014). In one study, the majority of medical students 
reporting NMPSU stated that they used prescription stimulants for “academic improvement” 
(Tuttle et al., 2010). Similarly, another study found that 70% of dental students with a history of 
NMPSU used stimulants “to improve attention and/or concentration” (McNiel et al., 2011). 
Additionally, medical students might be at higher at risk for NMPSU if they have easier access 
to prescription stimulants or increased knowledge of the drugs’ effects.  
Potential consequences of NMPSU. As with college students, medical students who use 
prescription stimulants are more likely to report other types of drug use (Emanuel et al., 2013). 
For example, one study found that prescription stimulant use during medical school is positively 
correlated with ecstasy use (Emanuel et al., 2013). Similarly, a study of pharmacy students 
indicated that students who report prescription stimulant use during pharmacy school are 4.5 
times more likely to endorse other illicit drug use (Volger et al., 2014). As previously mentioned, 
NMPSU also places individuals at risk for physical health consequences, including insomnia, 
seizures, cardiovascular problems, and sudden death. Finally, medical students may experience 
the same consequences of NMPSU as college students, including depression, anxiety, stress, and 
lower grade point averages (Gomes et al., 2011; McCabe et al., 2005; Sussman et al., 2006).  
Expectancy effects. Given the potential consequences of NMPSU, there have been 
increasing efforts to understand and prevent this behavior in recent years. There is evidence that 
individuals’ expectancies, or their expectations about a drug’s effects, can predict drug use 
(Torrealday et al., 2008). According to expectancy theory, habits are created and maintained 
when people predict that those behaviors will have positive consequences (Torrealday et al., 
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2008). Expectancies have been shown to predict many types of drug use, including marijuana, 
cocaine, alcohol, and cigarette use (Torrealday et al., 2008). For example, positive expectations 
for alcohol use are correlated with the age of onset and continuation of drinking (Torrealday et 
al., 2008). Similarly, expectancies mediate the perceived effects of nicotine in individuals who 
smoke cigarettes and predict feelings of alertness and calmness in those who ingest caffeine 
(Kelemen, 2008; Schneider et al., 2006).  
Several research efforts have focused on developing questionnaires to better understand 
the types of expectancies that predict drug use. For example, the Marijuana Effect Expectancy 
Questionnaire can be used to predict past and future marijuana use (Torrealday et al., 2008). 
Looby and Earleywine (2009) developed the Prescription Stimulant Expectancy Questionnaire 
(PSEQ) as a tool for assessing prescription stimulant use expectancies. The PSEQ originally 
contained 40 items, including 20 designed to reflect positive expectancies and 20 designed to 
reflect negative expectancies. Preliminary research on the PSEQ suggests that positive 
expectancies, but not negative expectancies, predicted the frequency of prescription stimulant 
use (Looby & Earleywine, 2009).  
After gaining a better understanding of motives for prescription stimulant use through the 
first study, Looby and Earleywine (2010) revised the test items to create the Prescription 
Stimulant Expectancy Questionnaire–II  (PSEQ–II). The PSEQ–II contains 11 new items that 
reflect expectations related to mood and cognitive enhancement, both of which were commonly 
expressed by participants in the earlier study (Looby & Earleywine, 2009).  
In their study of adults in the general population, Looby and Earleywine (2010) identified 
four factors that best account for variability in prescription stimulant use which they labeled:  
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(a) Cognitive Enhancement, (b) Anxiety and Arousal (c) Social Enhancement, and (d) Guilt and 
Dependence. The researchers then created composites of these factors to represent global 
positive expectancies (Cognitive Enhancement and Social Enhancement) and global negative 
expectancies (Anxiety and Arousal and Guilt and Dependence). The results of Looby and 
Earleywine’s (2010) study suggest that the PSEQ–II can reliably discriminate among different 
prescription stimulant user groups (i.e., nonusers, medical users, nonmedical users, 
medical/nonmedical users) in the general population. Specifically, individuals who reported both 
medical and nonmedical use of prescription stimulants reported the strongest positive 
expectancies, while nonusers reported the weakest positive expectancies (Looby & Earleywine, 
2010). In addition, research suggests that nonusers held the strongest negative expectancies while 
medical users held the weakest negative expectancies (Looby & Earleywine, 2010).  
Statement of the Problem 
A major limitation of previous research on the PSEQ–II is that samples were comprised 
largely of college students (Looby & Earleywine, 2009, 2010). Although college students are at 
high risk for NMPSU, recent research suggests that medical students are also at increased risk 
(Pilkinton & Cannatella, 2012; Emanuel et al., 2013; Wasserman et al., 2014; Volger et al., 
2014). The usefulness and applicability of the PSEQ–II to the medical student population has not 
been assessed. Given that medical students may have more knowledge about prescription 
stimulants and more exposure to them than the average person, their expectancies for 
prescription stimulant use may be different (Wasserman et al., 2014). As such, their responses on 
the PSEQ–II may not follow the same pattern found in previous studies, and their responses may 
or may not be predictive of their prescription stimulant use habits. Considering the intense 
cognitive demands and stress associated with medical school, it was predicted that expectancies 
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related to cognitive enhancement and anxiety and arousal would be most predictive of past 
prescription stimulant use and plans for future use.  
Purpose 
 The present study investigated the usefulness of the Prescription Stimulant Expectancy 
Questionnaire–II  (PSEQ–II) in identifying and classifying different types of prescription 
stimulant users in the medical student population. Research suggests that the PSEQ–II can 
reliably identify individuals at risk for NMPSU in the general population, but whether it can also 
do so for the medical student population has not been determined (Looby & Earleywine, 2010). 
If the PSEQ–II can predict the prescription stimulant use habits of medical students based on 
their expectancies, it may be possible to intervene with problematic expectancies to reduce the 
risk of NMPSU in this population (Looby & Earleywine, 2010; Looby, De Young, & 
Earleywine, 2013). Based on previous research, reducing the rate of NMPSU among medical 
students could also reduce their levels of stress, psychological symptoms, physical health 
problems, and substance abuse (McCabe et al., 2005).  
Research Questions  
1. Can the PSEQ–II discriminate among prescription stimulant user types (e.g., 
nonusers, medical users, nonmedical users, medical/nonmedical users) in the medical 
student population?  
2. Can the PSEQ–II discriminate among prescription stimulant user types in the medical 
student population when ADHD symptoms are controlled for?   
3. What types of expectancies best predict medical students’ past prescription stimulant 
use and plans for future use?  
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4. Can positive and/or negative expectancies predict medical students’ past prescription 
stimulant use and plans for future use?  
Method 
Participants 
A total of 119 individuals participated in the study. Participants were individuals over the 
age of 18 who were currently enrolled as full-time medical students in the United States. 
Recreational users, medical users, and nonusers of prescription stimulants were all invited to 
participate. Participants were recruited through Amazon Mechanical Turk, a website that allows 
researchers to specify a specific population to sample. There is considerable disagreement 
regarding the number of participants required for exploratory factor analysis, but several studies 
suggest that 100 participants is an adequate sample size (Williams, Brown, & Onsman, 2012; 
Costello & Osborne, 2005). Participants received $5 as compensation for completing the survey.  
Procedure 
 Participants were able to access the survey website from any computer, which increased 
confidentiality by allowing them to remain anonymous. Participants were then asked to complete 
a background survey that included questions about demographic information and prescription 
stimulant use history (See Appendix A). Specifically, participants were asked whether they had 
ever in their lifetime used a prescription stimulant for any purpose. If so, they were asked 
whether they had used the prescription stimulant for nonmedical purposes (i.e., taken a 
prescription stimulant prescribed for someone else or taken a prescription stimulant not as 
prescribed). Participants who reported lifetime use of prescription stimulants were asked whether 
they had a valid prescription for the medication and their motives for use. Participants were also 
asked to complete the 45-item Prescription Stimulant Expectancy Questionnaire–II (PSEQ–II) 
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and an 18-item questionnaire assessing for symptoms of ADHD. The entire survey took 
approximately 10 to 15 minutes to complete. 
Prescription Stimulant Expectancy Questionnaire–II. The present study employed a 
slightly shortened version of the PSEQ–II developed by Looby and Earleywine (2010; see 
Appendix A). Looby and Earleywine both permitted the use of the PSEQ–II for my research (see 
Appendix B). The PSEQ–II is a questionnaire that measures expectancy effects for prescription 
stimulants among individuals with varying histories of prescription stimulant use. Participants 
were asked to respond to each question on the PSEQ–II by indicating whether they would expect 
to experience each effect when using a prescription stimulant. Although a 7-point Likert scale is 
considered standard for most psychological studies, the PSEQ–II is formulated on a 3-point 
Likert scale ranging from 0 (not at all) to 2 (very often or always).  
The original PSEQ–II contains 51 items, but two items (“I focus on unimportant tasks” 
and “I can’t focus on more than one thing at a time”) were removed from the questionnaire 
because previous research indicated that they did not significantly load onto any factor (Looby & 
Earleywine, 2010). In addition, four items (“I am more likely to use drugs and/or alcohol,” “I 
don’t want to study/work without it,” “I get annoyed with myself for taking it,” and “I wish I 
could do as well without it”) were removed because they cross-loaded onto multiple factors in 
the previous study (Looby & Earleywine, 2010). Therefore, the present study employed a version 
of the PSEQ–II with only 45 questions, which made the questionnaire somewhat less 
burdensome for participants. 
ADHD Symptoms Questionnaire. Participants were asked to complete an 18-item 
questionnaire that assessed for symptoms for ADHD (Span, Earleywine, and Strybel, 2002; see 
Appendix A). This questionnaire was selected by Looby & Earleywine (2010) over other 
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measures because of its reliability with the adult population and because it equally assesses 
symptoms of inattention, hyperactivity, and impulsivity. Although the original ADHD 
Symptoms Questionnaire uses a 7-point Likert scale, Looby and Earleywine (2010) used a  
5-point Likert scale. In order to replicate their study as closely as possible, a 5-point Likert scale 
ranging from 0 (never) to 4 (very often or always) was used. Keeping with the instructions of the 
original study, participants who reported prescription stimulant use were asked to report how 
they feel when not using prescription stimulants in order to best assess ADHD symptoms.  
Statistical Analyses 
All data were analyzed using SPSS for Windows. To understand the underlying factor 
structure of the PSEQ–II, an exploratory factor analysis was conducted using principal axis 
factoring. Once the factors were identified, they were assessed for internal consistency and 
convergent validity. Multivariate analyses of variance (MANOVAs) were then conducted to 
differentiate among prescription stimulant user types based upon these factors. Following the 
MANOVAs, Roy Bargman stepdown analysis was employed to examine the differences among 
factors. Scheffé post-hoc tests were then examined to determine the specific differences among 
user types. Finally, multivariate analyses of covariance (MANCOVAs) were conducted to 
examine factor differences while controlling for ADHD symptoms.  
In order to assess what types of expectancies best predict prescription stimulant use in 
medical students, multiple linear regressions were conducted. If the multivariate effect was 
significant, the correlations between that factor and various indices of prescription stimulant use 
(lifetime use, lifetime nonmedical use, use in the past three years, use in the past year, use in the 
past three months, and plans for future use) were examined.  
 
PRESCRIPTION STIMULANT USE AMONG MEDICAL STUDENTS 
 
13 
Results 
Descriptive Statistics 
A total of 119 individuals participated in the study. Prior to data analyses, four 
participants were eliminated from the sample because they indicated that they were not full-time 
medical students. The resulting sample consisted of 115 participants: 67 male, 47 female, and 
one participant who did not provide gender information. Thirty-five participants were between 
the ages of 18 and 24, 74 were between the ages of 25 and 34, and 6 were 35 or older. Of those 
sampled, 28 were in their first year of medical school, 53 were second-year students, 24 were 
third-year students, one was a fourth-year student, six were completing internships, two were 
completing residencies, and one was completing a fellowship. 
Fifty-seven percent of those sampled (n = 66) reported lifetime prescription stimulant use 
and 43% (n = 49) reported lifetime nonmedical use. Twenty-five percent indicated that they 
might use prescription stimulants in the future and 34% indicated that they planned to do so. Of 
those who endorsed past prescription stimulant use, the most commonly reported motivations 
were to improve attention/concentration (n = 61), to work more efficiently (n = 54), and to stay 
awake (n = 46). Less commonly reported motivations were to enhance exercise/athletic 
performance (n = 8), to lose weight (n = 6), and to get high (n = 6). Users of prescription 
stimulants scored an average of 48.78 on the ADHD symptom scale (SD = 14.39) and non-users 
scored an average of 40.25 (SD = 9.81), which was significantly different (t(111) = 3.55, p < 
.01).  
Expectancy Scale Structure 
To assess the underlying factor structure of the PSEQ–II, an exploratory factor analysis 
was conducted using principal axis factoring with an oblique rotation (i.e., direct oblimin with 
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Kaiser normalization). The Kaiser-Meyer-Olkin measure of sampling adequacy and Bartlett’s 
test of sphericity were examined to determine whether or not the data was factorable. The 
Kaiser–Meyer–Olkin measure was greater than .6 and Bartlett’s test of sphericity was less than 
.001, suggesting that the correlation matrix was not an identity matrix and that the data was 
likely factorable. Next, the scree plot was examined to determine the number of valid factors. 
According to Tabachnick and Fidell (2007, as cited by Looby & Earleywine, 2010), the point at 
which the slope changes corresponds to the valid number of factors. The slope of the scree plot 
suggested that there were four valid factors.  
A second EFA was then conducted to force exactly four factors. Variables were defined 
as within a factor if they were greater than |.32| using the pattern matrix (Tabachnick & Fidell, 
2007 as cited by Looby & Earleywine, 2010). Using this criterion, four items failed to load onto 
a factor (“I absorb material the first time through,” “I feel like I can’t get through the day without 
it,” “It’s no trouble to sit still,” and “I get nervous and edgy”). In addition, five factors  
cross-loaded onto multiple factors (“I can ignore distractions more easily,” “I feel drained the 
next day,” “I feel like I’m cutting corners to do well,” “I’m all amped up,” and “I feel more 
confident in myself”). A third EFA was then conducted with these items removed. In examining 
this EFA, no items loaded onto the fourth factor, so a fourth and final EFA was conducted to 
force exactly three factors. 
Table 1 shows the Eigenvalues and explained variance for each of the factors from the 
final analysis. Factor 1 consisted of items related to enhanced concentration and cognitive skills 
(e.g., “I can pay attention really well”) and was labeled “Cognitive Enhancement” (see Table 2). 
Factor 2 consisted of items related to negative physiological symptoms (e.g., “I feel twitchy”) 
and was labeled “Anxiety and Arousal” (see Table 3). Factor 3 consisted of items related to 
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improved social abilities (e.g., “Conversing with others is easier”) and was labeled “Social 
Enhancement” (see Table 4). All three factors had good internal consistency. Cronbach’s alphas 
were .94 for Factor 1, .88 for Factor 2, and .80 for Factor 3.  
Research Question 1 
To assess whether the PSEQ–II could discriminate among prescription stimulant user 
types, participants were classified into four groups based on past prescription stimulant use:  
(a) non-users (n = 49), (b) nonmedical users (n = 3), (c) medical users (n = 15), and  
(d) medical/nonmedical users (n = 46). Of note, two individuals could not be classified because 
they endorsed past prescription stimulant use, but denied using them for either medical or 
nonmedical purposes. Additionally, given that only three respondents could be classified as 
exclusively nonmedical users, this group was not included in analyses comparing user groups.  
One-way ANOVAs were performed to examine any differences in age, gender, or school 
year among user groups. No significant differences in age (x2 = 1.46, p = .521), gender (x2 = .02, 
p = .92), or school year (x2 = 1.95, p = .66) were observed among user groups.  
A MANOVA was then conducted to examine factor scale differences among user groups 
(see Table 5). Using Pillai’s Trace, the multivariate effect for user type was significant (F(6, 212) 
= 5.25, p < .001) and significant differences were observed among user groups on the Cognitive 
Enhancement factor (F(2, 109) = 10.23, p < .001) and the Anxiety and Arousal factor (F (2, 109) 
= 8.55, p < .01). No significant differences were found among user groups on the Social 
Enhancement factor (F (2, 109) = 1.90, p = .16). 
Sheffé post-hoc tests were then used to evaluate the differences among user types for 
each factor (see Table 5). On the Cognitive Enhancement scale, nonusers scored significantly 
lower than medical users or medical/nonmedical users. Medical users held the strongest beliefs 
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about cognitive enhancement, followed by medical/nonmedical users and nonusers respectively. 
On the Anxiety and Arousal scale, nonusers scored significantly higher than medical users or 
medical/nonmedical users, with nonusers holding the most beliefs, followed by medical users 
and medical/nonmedical users respectively. On the Social Enhancement scale, none of the 
groups significantly differed from one another. 
Research Question 2 
To further clarify the relationship between expectancies and user type, a MANCOVA 
was conducted while controlling for ADHD symptoms (see Table 6). Controlling for ADHD 
symptoms did not change the relationship between PSEQ–II factors and user type. Using Pillai’s 
Trace, the multivariate effect among groups remained significant (F(6, 206) = 5.63, p < .001). 
Furthermore, the effects for the Cognitive Enhancement factor (F(2, 108) = 8.43, p < .001) and 
the Anxiety and Arousal factor (F(2, 108) = 12.74, p < .001) remained significant. There was 
still no significant effect for the Social Enhancement factor (F(2, 108) = .88, p = .42).  
Research Question 3 
In order to assess what types of expectancies best predict prescription stimulant use in 
medical students, multiple linear regressions were conducted. The multivariate effect for 
Cognitive Enhancement was significant (R2 = .26, F(7, 114) = 5.23, p < .001). The correlations 
between Cognitive Enhancement and prescription stimulant use (lifetime use, lifetime 
nonmedical use, use in the past three years, use in the past year, use in the past three months, and 
plans for future use) were then examined. Cognitive Enhancement significantly predicted use in 
the past three months (b = .45, t(108) = 2.52, p < .05).  
The multivariate effect for Anxiety and Arousal and prescription stimulant use was also 
significant (R2 = .20, F(7, 114) = 3.72, p < .01). When the correlations between Anxiety and 
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Arousal and various indices of use were examined (see Table 8), Anxiety and Arousal was 
significantly predictive of lifetime use (b = -.51, t(108) = -2.24, p < .05) and use in the past 
month (b = -.28, t(108) = -2.20, p < .05). 
The multivariate effect for Social Enhancement and prescription stimulant use was not 
significant (R2 = .11, F(7, 114) = 1.82, p = .90).  
Research Question 4 
To examine positive and negative expectancies more generally, a global positive scale 
was created by combining the Cognitive Enhancement factor and the Social Enhancement factor. 
The multivariate effect among indices of use was significant (R2 = .21, F(7, 114) = 5.25, p < 
.001). When the correlations between Positive Expectancies and various indices of use were 
examined (see Table 9), the Positive Expectancies scale was significantly predictive of use in the 
past three months (b = .56, t (114) = 3.08, p < .005). 
As previously mentioned, the Anxiety and Arousal factor, which represented negative 
expectancies, was also significantly predictive of prescription stimulant use (R2 = .20, F(7, 114) 
= 3.72, p < .01). More specifically, Anxiety and Arousal was significantly predictive of lifetime 
use (b = -.51, t(108) = -2.24, p < .05) and use in the past month (b = -.28, t(108) = -2.20, p < .05). 
Discussion 
PSEQ–II Factor Structure 
 In terms of the underlying factor structure of the PSEQ–II, the present results differ 
slightly from earlier findings in that three factors were observed, rather than four. However, the 
factors themselves are consistent with those found by Looby and Earleywine (2010). 
Specifically, factors related to (a) cognitive enhancement, (c) social enhancement, and  
(c) anxiety and arousal were identified.  
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The fact that there was no factor for guilt and dependence suggests that participants 
responded inconsistently to items related to this topic. One possible explanation for this finding 
is that medical students might feel more ambivalence about prescription stimulant use than the 
general population. In other words, they might feel somewhat guilty about using prescription 
stimulants, but they might also believe that their use is justified. Previous research indicates that 
people feel less guilty about using prescription stimulants if they can mentally justify it (Judson 
& Langdon, 2009). Given the cognitive demands, stress levels, and competitive nature of 
medical school (Wasserman et al., 2014), it is easy to imagine how medical students might 
justify their use.  
It is also possible that medical students have different knowledge of prescription 
stimulant effects than the average person, leading them to discriminate among various 
dependency effects more than a layperson. For example, the average college student might 
endorse global, generalized expectations of dependence, whereas a medical student might 
believe that certain dependency symptoms are more likely than others. 
Finally, it is worth noting that the original Guilt and Dependency factor was the weakest 
and least predictive of the four factors identified by Looby and Earleywine (2010). In the 
aforementioned study, Guilt and Dependence explained just 2.83% of the variance among 
PSEQ–II items in comparison to the 24.63% explained by the Cognitive Enhancement factor. 
Therefore, the present findings are probably not an extreme departure from earlier findings. 
Furthermore, the original Guilt and Dependence factor consisted of just five items. Of these 
items, two were removed from the present study prior to the final factor analysis because they 
either failed to load onto a factor (“I feel like I can’t get through the day without it”) or  
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cross-loaded onto multiple factors (“I feel like I’m cutting corners to do well”). The removal of 
these items likely contributed to the disappearance of this factor from the factor analysis.  
Ability to Discriminate Among User Types 
Users versus nonusers. The present results support previous findings that the PSEQ–II 
can effectively discriminate among certain prescription stimulant user types. As suggested by 
Looby & Earleywine (2010), nonusers appear to hold the strongest beliefs about anxiety and 
arousal and the weakest beliefs about cognitive enhancement (Looby & Earleywine, 2009,  
2010).  
Conceptually, these findings are logical for several reasons. First of all, individuals who 
do not expect cognitive benefits would have less motivation to use prescription stimulants than 
individuals who expect such effects. Similarly, individuals who expect to feel anxious or 
physiologically aroused would probably be more likely avoid prescription stimulant use. An 
alternative explanation is that nonusers had never considered negative side effects, but endorsed 
them during the study as a way of mentally justifying why they had not used prescription 
stimulants. If nonusers endorsed expectations about cognitive enhancement, which they did to 
some degree, but not anxiety and arousal, it would have left them with a sense of cognitive 
dissonance. In other words, if they expected prescription stimulants to have positive effects, but 
not negative effects, they might have questioned why they had never tried them. In the same 
way, medical and medical/nonmedical users might have exaggerated their beliefs about cognitive 
enhancement and downplayed their beliefs about anxiety and arousal in order to minimize 
cognitive dissonance about using them. Finally, it is possible that medical and 
medical/nonmedical users legitimately experience cognitive enhancement without anxiety or 
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arousal. Nonusers might hold different beliefs about these effects simply because they have 
never tried them. 
 Medical users versus medical/nonmedical users. While the PSEQ–II was effective at 
discriminating prescription stimulant users from nonusers, it was not effective at distinguishing 
medical users from medical/nonmedical users. Thus, Looby and Earleywine’s (2010) findings do 
not completely generalize to the medical student population. Among medical students, medical 
users and medical/nonmedical users did not significantly differ from one another in terms of their 
expectancies about either cognitive enhancement or anxiety and arousal.  
There are several possible explanations for this discrepancy. First, it is possible that 
medical and medical/nonmedical users do not significantly differ in terms of their prescription 
stimulant use expectancies, which would make the PSEQ–II ineffective at distinguishing 
between these two groups. Perhaps medical students’ experience with prescription stimulants, 
combined with their knowledge of drug effects, causes them to hold expectancies that are 
relatively similar to one another. Alternatively, the two user groups might hold expectancies that 
were not adequately assessed by the PSEQ–II (i.e., unrelated to cognitive enhancement, social 
enhancement, anxiety and arousal, or guilt and dependence). There might be a different category 
of beliefs or a different way of wording those items that would be more relevant to medical 
students. Finally, it is possible that the PSEQ–II could not discriminate between medical users 
and medical/nonmedical users because of how these constructs were defined. To the extent that 
ADHD is over-diagnosed in the medical student population, the line between medical and 
nonmedical use is somewhat unclear. As previously mentioned, ADHD is estimated to occur in 
4.4% of adults in the United States (Pilkinton & Cannatella, 2012), but an overwhelming 53% of 
medical students sampled in the present study reported lifetime possession of a prescription for 
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stimulants. As such, participants might have classified their use as medical because they took 
their medications as prescribed. However, if they should not have been diagnosed with ADHD in 
the first place, it raises questions about whether their use should truly be considered medical.  
Although the ADHD Symptom Questionnaire can help by clarifying the extent of ADHD 
symptoms, the presence of symptoms alone does not necessarily warrant a diagnosis or medical 
prescription. Many typically developing individuals experience problems with concentration, 
restlessness, and forgetfulness when placed in stressful environments or when deprived of sleep. 
As such, some level of these symptoms might be expected of medical students, even if they did 
not have ADHD. In addition, it is possible that medical students’ self-reports were not an 
accurate reflection of their true symptom presentation. For example, medical students might have 
exaggerated their reporting of ADHD symptoms in order to reduce cognitive dissonance about 
prescription stimulant use. Alternatively, they might perceive that average levels of attention and 
concentration are abnormal because they are surrounded by high-achieving peers. 
Ability to Predict Prescription Stimulant Use 
The present study’s results support earlier findings that the PSEQ–II can predict past 
prescription stimulant use (Looby & Earleywine, 2009). Specifically, the Cognitive 
Enhancement and Positive Expectancies scales were predictive of use in the past three months. 
In contrast to earlier findings, the Anxiety and Arousal scale was also predictive of lifetime 
prescription stimulant use and use in the past month. Specifically, individuals with stronger 
expectancies related to anxiety and arousal were less likely to report past prescription stimulant 
use. One possible explanation for this discrepancy is a difference in methodology. Looby and 
Earleywine (2009) assessed the frequency of past prescription stimulant use, whereas the present 
study investigated the presence or absence of use across different time periods (i.e., lifetime use, 
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lifetime nonmedical use, use in the past three years, use in the past year, use in the past three 
months, use in the past month). Therefore, negative expectancies might predict the presence or 
absence of past use, or the recency of such use, but not the frequency. It is also possible that 
negative expectancies predict prescription stimulant use among medical students, but not 
members of the general population. This could be due to factors that differentiate medical 
students from the general population, such as higher levels of stress and anxiety, reduced sleep, 
or increased knowledge of medication effects. 
The present study also extended previous research by investigating plans for future use. 
The results suggest that the PSEQ–II is not predictive of medical students’ plans for future use. 
However, it does appear to predict medical students’ lifetime use, use in the past three months, 
and use in the past month, any of which might be correlated with future use. 
Prevalence of Prescription Stimulant Use Among Medical Students 
 Of the medical students who participated in the present study, 57% reported lifetime 
prescription stimulant use and 43% endorsed lifetime NMPSU. These rates exceed those 
reported in earlier studies of this population. On one hand, the present results might be an 
overestimate of prescription stimulant use. It is possible that individuals with a history of 
prescription stimulant use were more interested in the study and therefore more inclined to 
participate. On the other hand, these rates might reflect a legitimate increase in prescription 
stimulant use over the past few years. The rates of ADHD diagnosis and prescription stimulant 
treatment continue to increase steadily, especially among college students (Bavarian et al., 2013; 
Varga, 2012). If the demands of college remain the same or increase in medical school, one 
might expect that students who used prescription stimulants in college would continue to do so in 
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medical school. Additionally, students who refrained from using prescription stimulants in 
college might begin doing so in medical school if the demands increase. 
Finally, it is possible that the present findings are actually an underestimate of NMPSU in 
this population. If ADHD is being over-diagnosed in this population, then perhaps some of this 
prescription stimulant use should not be considered medical. Even when nonmedical users are 
excluded from the equation, the fact that 14% of participants were classified as medical users is 
concerning. It is possible that all of these students were honest with their prescribers and 
legitimately believed that they had ADHD. However, the comparatively high rate of ADHD 
diagnosis in this population suggests that psychiatrists and medication providers should be 
cautious when assessing this population.  
Limitations 
It is important to consider several potential limitations of this study. First, the data 
consisted of anonymous self-reports. Participants’ responses may have been biased if they were 
motivated by monetary gain. For example, they might have responded quickly and randomly 
with the sole goal of monetary acquisition. Additionally, they might have responded in a way 
that they hoped would be consistent with the researcher’s preferences, in order to insure that they 
would be rewarded for their time. Furthermore, the anonymous nature of the survey might have 
contributed to reduced feelings of personal responsibility, allowing participants to respond more 
randomly or less truthfully. Another limitation of this study is the exclusion of exclusively 
nonmedical users from analyses. However, it is possible that exclusively nonmedical users are 
rare within the medical student population, which would make examining this group less 
meaningful or urgent. Finally, another limitation of this study is that it examined prescription 
stimulant use across various time frames, but did not investigate the frequency of such use. It is 
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possible that information about frequency would enhance understanding about the PSEQ–II’s 
applicability to the medical student population. For the sake of prevention and intervention 
efforts, it would be useful to understand how often medical students use prescription stimulants. 
Conclusions and Directions for Future Research 
Taken as a whole, the number of medical students who indicated that they might use 
(25%) or planned to use (34%) prescription stimulants in the future is alarming. Nonmedical 
prescription stimulant use is associated with a number of negative outcomes, including lower 
grade point averages and increased rates of drug and alcohol abuse, mental illness, and physical 
health problems (Emanuel et al., 2013; McCabe et al., 2005; Volger et al., 2014). Fortunately, 
the present findings should be useful in informing future research and intervention efforts for this 
population. In general, medical students appear to be at greater risk for prescription stimulant use 
if they hold strong expectancies related to cognitive enhancement and weak expectancies related 
to anxiety and arousal. Therefore, future research should explore interventions that alter these 
beliefs. For example, practitioners might challenge these beliefs through cognitive-behavioral 
therapy or Motivational Interviewing. Researchers might also explore the usefulness of 
psychoeducation in encouraging more realistic or safe beliefs about prescription stimulants. 
Given the prevalence of prescription stimulant use among medical students, medical schools 
should consider implementing widespread preventative and intervention efforts of their own. 
Finally, medical providers should be educated about the prescription stimulant use habits of 
medical students and adopt a careful, conservative attitude when diagnosing ADHD or 
prescribing stimulants to members of this population. 
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Note. Following the PSEQ–II, participants completed the ADHD Symptoms Questionnaire 
derived from Span, Earleywine, and Strybel (2002). These items are not included here because 
permission was not obtained. 
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Appendix B 
Permission to Use the PSEQ–II 
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Table 1 
Eigenvalues and Explained Variance of PSEQ–II Factors 
Factor Eigenvalue Explained Variance 
 
Factor 1 – Cognitive Enhancement 
 
9.49 
 
26.37% 
 
Factor 2 – Anxiety and Arousal 5.00 13.90% 
Factor 3 – Social Enhancement 2.96 8.22% 
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Table 2 
Factor Loadings for Cognitive Enhancement Factor 
PSEQ–II Item Factor Loading 
 
22. Distractions disappear 
 
.58 
26. I can pay attention really well .77 
27. I can study/work for hours .61 
31. I don’t end up daydreaming .40 
32. I enjoy studying/work a lot more .51 
40. I learn/work very efficiently .74 
41. I need fewer breaks when I study/work .81 
46. My ability to focus is better .89 
47. My concentration is excellent .88 
48. My focus is crystal clear .75 
51. My mind doesn’t wander .62 
52. My mind is razor sharp .78 
53. My thoughts follow more logically .51 
57. I can focus really well .72 
62. My memory is better .64 
65. My thoughts stay on track better .78 
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Table 3 
Factor Loadings for Anxiety and Arousal Factor 
PSEQ–II Item Factor Loading 
 
28. I can’t hold still 
 
.52 
29. I can’t sleep even if I want to .52 
37. I feel sick to my stomach .54 
38.  I feel high .50 
42. I worry that I’m addicted to it .72 
45. I’ve come to see it as a crutch .61 
49. My head hurts .65 
56. My heart races .76 
58. I can’t calm down .71 
59. I feel twitchy .72 
63. I feel guilty for taking it .63 
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Table 4 
Factor Loadings for Social Enhancement Factor 
PSEQ–II Item Factor Loading 
 
24. I feel very happy 
 
.51 
30. I enjoy parties more .53 
34. Conversing with others is easier .62 
39. I am friendlier .60 
50. I’m free to be myself and do whatever I want to do .51 
54. I feel more relaxed in social situations .59 
55. My work seems more interesting .43 
60. I feel as though everything is right in the world .48 
66. I laugh more .68 
 
PRESCRIPTION STIMULANT USE AMONG MEDICAL STUDENTS 
 
42 
Table 5 
Mean Differences in Factor Scale Scores Among User Groups 
 Group 1  
(Medical/Nonmedical) 
Group 2  
(Medical Users) 
Group 3  
(Nonusers) 
 
Factor  M SD M SD M SD F(2, 109) p value Post-Hoc Tests  
Cognitive  40.37 5.44 40.93 5.71 34.86 7.59 10.23 .000* 1, 2>3 
Anxiety  18.26 4.58 18.27 3.90 21.96 4.93 8.55 .000* 1, 2<3 
Social  18.33 3.56 17.73 3.79 16.81 3.99 1.90 .155  
Note. * Correlation is significant at the .001 level (2-tailed).  
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Table 6 
Mean Differences in Factor Scale Scores Among User Groups while Controlling for ADHD 
 Group 1 
(Medical/Nonmedical) 
Group 2 
(Medical Users) 
Group 3  
(Nonusers) 
 
Factor  M SD M SD M SD F(2,108) p value Post-Hoc Tests 
Cognitive 40.44 5.48 40.93 5.71 34.64 7.53 8.43 .000* 1, 2>3 
Anxiety 18.00 4.27 18.27 3.90 21.94 4.98 12.74 .000* 1, 2<3 
Social 18.47 3.47 17.73 3.79 16.73 3.99 .876 .42  
Note. * Correlation is significant at the .001 level (2-tailed).  
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Table 7 
Standardized Beta Weights, t values, and p values for Cognitive Enhancement Factor 
Index of Use b t p 
All indices of use  18.938 .000** 
Lifetime use .21 .97 .34 
Lifetime nonmedical use .22 1.48 .14 
Use in the past three years .13 .68 .50 
Use in the past year .04 .16 .87 
Use in the past three months .45 2.52 .01* 
Use in the past month .08 .68 .50 
Plans for future use .06 .53 .60 
Note. * Correlation is significant at the .05 level (2-tailed). ** Correlation is significant at the 
.001 level (2-tailed).  
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Table 8 
Standardized Beta Weights, t values, and p values for Anxiety and Arousal Factor 
Index of Use b t p 
All indices of use  8.88 .000** 
Lifetime use .51 2.24 .03* 
Lifetime nonmedical use .18 1.12 .29 
Use in the past three years .22 1.08 .21 
Use in the past year .34 1.27 .91 
Use in the past three months .02 .16 .03* 
Use in the past month .28 2.20 .27 
Plans for future use .11 .89 .37 
Note. * Correlation is significant at the .05 level (2-tailed). ** Correlation is significant at  
the .001 level (2-tailed).  
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Table 9 
Standardized Beta Weights, t values, and p values for Positive Expectancies Factor 
Index of Use b t p 
All indices of use  20.77 .000** 
Lifetime use .30 1.38 .17 
Lifetime nonmedical use .25 1.64 .10 
Use in the past three years .08 .40 .69 
Use in the past year .13 .51 .62 
Use in the past three months .56 3.08 .003* 
Use in the past month .01 .04 .97 
Plans for future use .08 .67 .50 
Note. * Correlation is significant at the .005 level (2-tailed). ** Correlation is significant at the 
.001 level (2-tailed).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
